SI2922530T1 - Formulacije kaspofugin acetata - Google Patents

Formulacije kaspofugin acetata

Info

Publication number
SI2922530T1
SI2922530T1 SI201230815A SI201230815A SI2922530T1 SI 2922530 T1 SI2922530 T1 SI 2922530T1 SI 201230815 A SI201230815 A SI 201230815A SI 201230815 A SI201230815 A SI 201230815A SI 2922530 T1 SI2922530 T1 SI 2922530T1
Authority
SI
Slovenia
Prior art keywords
caspofungin acetate
acetate formulations
formulations
caspofungin
acetate
Prior art date
Application number
SI201230815A
Other languages
English (en)
Inventor
Zhi-Qiang Jiang
Arunya Usayapant
David Bowman
Keith Kwok
Joel Peterson
Original Assignee
Fresenius Kabi Usa, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Usa, Llc filed Critical Fresenius Kabi Usa, Llc
Publication of SI2922530T1 publication Critical patent/SI2922530T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI201230815A 2012-11-20 2012-12-21 Formulacije kaspofugin acetata SI2922530T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728406P 2012-11-20 2012-11-20
EP12810519.4A EP2922530B1 (en) 2012-11-20 2012-12-21 Caspofungin acetate formulations
PCT/US2012/071215 WO2014081443A1 (en) 2012-11-20 2012-12-21 Caspofungin acetate formulations

Publications (1)

Publication Number Publication Date
SI2922530T1 true SI2922530T1 (sl) 2017-04-26

Family

ID=47505366

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201230815A SI2922530T1 (sl) 2012-11-20 2012-12-21 Formulacije kaspofugin acetata

Country Status (15)

Country Link
US (4) US9636407B2 (sl)
EP (1) EP2922530B1 (sl)
CA (1) CA2888625A1 (sl)
CY (1) CY1120016T1 (sl)
DK (1) DK2922530T3 (sl)
ES (1) ES2607646T3 (sl)
HK (1) HK1215668A1 (sl)
HR (1) HRP20161703T1 (sl)
HU (1) HUE032392T2 (sl)
LT (1) LT2922530T (sl)
PL (1) PL2922530T3 (sl)
PT (1) PT2922530T (sl)
SI (1) SI2922530T1 (sl)
SM (1) SMT201600452B (sl)
WO (1) WO2014081443A1 (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2922530T (lt) * 2012-11-20 2017-01-25 Fresenius Kabi Usa, Llc Kaspofungino acetato kompozicijos
WO2017185030A1 (en) * 2016-04-22 2017-10-26 Fresenius Kabi Usa, Llc Caspofungin formulation with low impurities
CA3128398A1 (en) * 2018-02-01 2019-08-08 The Royal Institution For The Advancement Of Learning / Mcgill University Formulations for improving the delivery of hydrophobic agents
WO2019157453A1 (en) 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
CN109758426B (zh) * 2019-01-24 2021-04-27 四川制药制剂有限公司 一种注射用醋酸卡泊芬净药物组合物及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
ATE223226T1 (de) 1994-09-16 2002-09-15 Merck & Co Inc Azazyklohexapeptid-verbindungen
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5552521A (en) 1995-02-10 1996-09-03 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
USRE38984E1 (en) 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
US5936062A (en) 1997-06-12 1999-08-10 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
CN100448482C (zh) 1999-05-31 2009-01-07 三菱化学株式会社 Hgf冻干制剂
DE60103504T2 (de) 2000-01-20 2005-06-09 Basilea Pharmaceutica Ag Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen
US6803046B2 (en) 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP2340846A1 (en) 2006-07-26 2011-07-06 Sandoz Ag Caspofungin formulations
TW200826957A (en) 2006-10-16 2008-07-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Purification processes for echinocandin-type compounds
JP5537425B2 (ja) 2007-06-26 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 凍結乾燥抗真菌組成物
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
MX2010012451A (es) 2008-05-15 2010-12-07 Baxter Int Formulaciones farmaceuticas estables.
US20090291996A1 (en) 2008-05-21 2009-11-26 Ferenc Korodi Caspofungin free of caspofungin Co
US20090324635A1 (en) 2008-06-25 2009-12-31 Ferenc Korodi Caspofungin free of caspofungin impurity A
EP2240507A2 (en) 2008-06-25 2010-10-20 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Processes for preparing high purity aza cyclohexapeptides
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
TW201024322A (en) 2008-12-31 2010-07-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Preparation method for nitrogen containing heterocyclic hexapeptide with high conversion rate
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
US8951958B2 (en) 2010-03-29 2015-02-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Purification of caspofungin intermediates
KR20130136466A (ko) 2010-09-20 2013-12-12 셀리아 파마슈티칼즈 에이피에스 카스포펀진 조성물
WO2012041801A1 (en) 2010-09-28 2012-04-05 Dsm Sinochem Pharmaceuticals Netherlands B.V. Method for isolating a cyclohexapeptide
WO2012093293A1 (en) 2011-01-03 2012-07-12 Biocon Limited Process for preparation of caspofungin acetate and intermediates
CN102166186A (zh) 2011-04-18 2011-08-31 深圳市健元医药科技有限公司 一种更加稳定的氮杂环己肽类制剂
CN102746384B (zh) 2011-04-22 2016-01-20 上海天伟生物制药有限公司 一种高纯度的卡泊芬净或其盐及其制备方法和用途
MX2013012161A (es) 2011-04-28 2014-07-30 Unitris Biopharma Co Ltd Compuesto intermedio de la sintesis de caspofungina y metodo de preparacion de la misma.
LT2922530T (lt) * 2012-11-20 2017-01-25 Fresenius Kabi Usa, Llc Kaspofungino acetato kompozicijos
EP2992003B1 (en) 2013-05-02 2017-01-25 DSM Sinochem Pharmaceuticals Netherlands B.V. Method for isolating caspofungin
CN105531283A (zh) 2013-09-11 2016-04-27 中化帝斯曼制药有限公司荷兰公司 卡泊芬净衍生物

Also Published As

Publication number Publication date
HK1215668A1 (zh) 2016-09-09
HUE032392T2 (en) 2017-09-28
PT2922530T (pt) 2016-12-22
PL2922530T3 (pl) 2017-04-28
US20190105392A1 (en) 2019-04-11
SMT201600452B (it) 2017-01-10
DK2922530T3 (en) 2017-01-09
US20160310597A1 (en) 2016-10-27
WO2014081443A1 (en) 2014-05-30
US20170296667A1 (en) 2017-10-19
ES2607646T3 (es) 2017-04-03
CY1120016T1 (el) 2018-12-12
EP2922530B1 (en) 2016-09-14
US20140142032A1 (en) 2014-05-22
HRP20161703T1 (hr) 2017-03-10
CA2888625A1 (en) 2014-05-30
EP2922530A1 (en) 2015-09-30
LT2922530T (lt) 2017-01-25
US9636407B2 (en) 2017-05-02

Similar Documents

Publication Publication Date Title
HK1216008A1 (zh) 穩定的萬古黴素製劑
ZA201500212B (en) Progesterone formulations
PL3181128T3 (pl) Kompozycja farmaceutyczna nilotynibu
EP2910147A4 (en) CHAIR
AU345839S (en) Chair
EP2910148A4 (en) CHAIR
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
HUE058912T2 (hu) Liposzóma készítmények
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
HK1197193A1 (en) Sunscreen formulations
SI2916871T1 (sl) Proizvod ko-mikronizacije, ki vsebuje ulipristalacetat
EP2861218A4 (en) LIPOSOME FORMULATIONS
HK1215668A1 (zh) 醋酸卡泊芬淨製劑
PT2908835T (pt) Formulações estáveis
GB201200555D0 (en) Peptide
HK1203411A1 (en) Inulin and inulin acetate formulations
HK1209339A1 (en) Pharmaceutical formulations
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201219818D0 (en) Chair
GB201206178D0 (en) Formulations
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
AU343976S (en) Chair
AU343977S (en) Chair
AU343052S (en) Chair